바이오테크 보도자료
-
- Medidata Announces Rapid Expansion of its Sensor Cloud Network with the Addition of 10 Health Technology Innovators
- Medidata, a Dassault Systèmes company, announced 10 highly innovative organizations have joined its groundbreaking Sensor Cloud Network. AliveCor, Aural Analytics, Biobeat, Blue Spark Technologies, Glooko, Indie Health, University of Arizona, Carn...
- 2022년 07월 01일
-
- MRM Health Starts Clinical Trial with Next-Generation Optimized Consortium Therapeutic MH002 in Pouchitis
- MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced today that they have received regulatory approval from the Federal Agency for Medicines and Health Products (FAMHP)...
- 2022년 06월 30일
-
- GPS Announces New Senior Leadership Changes
- Global Processing Services (GPS), a leading global payment technology platform, has today announced the promotion of Joanne Dewar to Vice Chair. Kevin Schultz has also been appointed as Chief Executive Officer, effective immediately. Joanne will m...
- 2022년 06월 30일
-
- Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
- Takeda (TSE:4502/NYSE:TAK) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease ass...
- 2022년 06월 28일
-
- Asia Specific Biotechnology Instruments Market Is Poised To Exceed USD 40 Bn by 2032; R&D Arms of Major Multinational Pharmaceutical Corporations Fuels The Market: Report by Fact.MR
- The Biotechnology Instruments Market revenues were estimated at USD 46.1 Bn in 2021 and is anticipated to grow at a CAGR of 16.4% from 2022-2032, according to a recently published Fact.MR report. By the end of 2032, the market is expected to reach...
- 2022년 06월 22일
-
- Galderma Announces Positive Data From Phase III Trial, Demonstrating Efficacy and Safety of nemolizumab in Patients with Prurigo Nodularis
- Galderma today announced the phase III OLYMPIA 2 trial met all primary and key secondary endpoints, showing nemolizumab as monotherapy significantly improved skin lesions and pruritus (itch) compared with placebo in adult patients with moderate to...
- 2022년 06월 22일
-
- Waters and BioInfra Establish the ASEAN Academy for Bioanalysis to Promote Analytical Skills Development
- Waters Corporation (NYSE:WAT) announced a collaboration with BioInfra, a pioneering contract research organization (CRO) company for the pharmaceutical and clinical fields, to jointly establish the ASEAN Academy for Bioanalysis. The academy is ded...
- 2022년 06월 21일
-
- Companies in the Global Omics Based Clinical Trials Market Expedite Product Innovations to Stay at Forefront; Expected Sales to Reach USD 61.7 Bn By 2032: Fact.MR’s Study
- The Omics Based Clinical Trials Market revenues were estimated at USD 26.2 Bn in 2021 and is anticipated to grow at a CAGR of 8.1% from 2022 to 2032, according to a recently published Fact.MR report. By the end of 2032, the market is expected to r...
- 2022년 06월 21일
-
- AOP Health Presents Final Results From Its CONTINUATION-PV Study - up to 7.5 Years Treatment With BESREMi® (Ropeginterferon alfa-2b) of Polycythaemia Vera Patients - at EHA 2022 Annual Meeting
- AOP Health announced the final results on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from its CONTINUATION-PV study in an oral presentation at the prestigious EHA (European Hematology Association) 2022 Annual Meeting by Profe...
- 2022년 06월 21일
-
- AOP 헬스, EHA 2022 연례 회의서 ‘CONTINUATION-PV’ 연구 결과 발표… 베스레미(로페그인터페론알파-2b) 이용한 7년 6개월의 진성적혈구증가증 환자 치료 여정 마무리
- AOP 헬스(AOP Health)가 2022년 유럽혈액학회(EHA) 연례 회의에서 진성적혈구증가증(Polycythaemia Vera, 약칭 PV) 환자를 로페그인터페론알파-2b(Ropeginterferon alfa-2b)로 치료하는 ‘CONTINUATION-PV’ 연구의 최종 결과를 구두로 발표했다. 발표는 하인츠 기슬링...
- 2022년 06월 21일
전시회
